Compare OCS & NOAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCS | NOAH |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | Switzerland | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.3M | 462.0M |
| IPO Year | 2022 | 2010 |
| Metric | OCS | NOAH |
|---|---|---|
| Price | $7.50 | $6.53 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $35.89 | $10.29 |
| AVG Volume (30 Days) | 253.1K | ★ 303.3K |
| Earning Date | 11-03-2026 | 11-24-2026 |
| Dividend Yield | N/A | ★ 10.88% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $389.20 | N/A |
| P/E Ratio | ★ N/A | $13.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.78 | $6.24 |
| 52 Week High | $34.48 | $12.45 |
| Indicator | OCS | NOAH |
|---|---|---|
| Relative Strength Index (RSI) | 40.30 | 38.15 |
| Support Level | $6.95 | N/A |
| Resistance Level | $8.84 | $7.19 |
| Average True Range (ATR) | 0.65 | 0.21 |
| MACD | 0.06 | 0.00 |
| Stochastic Oscillator | 33.83 | 32.80 |
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.